Skip to content

Effect of Immersive Virtual Reality Exergames in Patients With Parkinson's Disease

Effect of Cognitively Challenging Exergames Using Fully Immersive Virtual Reality in Patients With Parkinson's Disease: A Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04787549
Enrollment
12
Registered
2021-03-08
Start date
2021-07-20
Completion date
2022-01-27
Last updated
2022-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Parkinson's disease, Virtual reality, Exergame

Brief summary

The study aimed to investigate the effect of applying cognitively challenging exergames using fully immersive virtual reality in patients with Parkinson's disease.

Detailed description

It has been reported that dual-task training involving both cognitive and physical functions helps improve walking speed during dual-task performance without increasing the fall risk in patients with Parkinson's disease (PD). Compared with conventional physical therapy, there are studies that dual-task training significantly improved walking speed and stride in PD patients. In addition, a systematic review study has been reported that it helps to improve balance and cognitive function when dual-task training is performed for patients with neurological diseases including Parkinson's disease. Virtual reality is expected to promote functional recovery in patients with neurological disorders in terms of providing an enriched environment, goal-directed tasks and repetition, and inducing interest and motivation. Therefore, the study aimed to investigate the effect of applying cognitively challenging exergames using fully immersive virtual reality in patients with PD.

Interventions

A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for exergames using fully immersive virtual reality under the assistance of an occupational therapist.

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinically diagnosed as idiopathic Parkinson's disease * Modified Hoehn & Yahr stage 2, 2.5, or 3

Exclusion criteria

* Moderate to severe cognitive dysfunction with Mini-mental State Examination score \< 19 * Severe dyskinesia or severe on-off phenomenon * Plan to adjust medication at the time of screening * Other brain diseases such as stroke, brain tumor, etc * History of seizure * Vestibular disease or paroxysmal vertigo * Other comorbidities that make it difficult to participate in this study

Design outcomes

Primary

MeasureTime frame
Physical dual-task interference (%) in Timed-up & go testat study completion, an average of 1 month
Cognitive dual-task interference (%) in Timed-up & go testat study completion, an average of 1 month

Secondary

MeasureTime frameDescription
Timed-up & go test (sec): cognitive dual-taskat study completion, an average of 1 month
Timed-up & go test (sec): physical dual-taskat study completion, an average of 1 month
The Unified Parkinson's Disease Rating Scaleat study completion, an average of 1 monthThe higher the score, the more negative the result
Berg balance scaleat study completion, an average of 1 monthThe higher the score, the more positive the result
Trail making testat study completion, an average of 1 month
Digit span testat study completion, an average of 1 month
New Freezing of Gait Questionnaire (NFOGQ)at study completion, an average of 1 month
Stroop testat study completion, an average of 1 month
Timed-up & go test (sec): single taskat study completion, an average of 1 month

Other

MeasureTime frame
Simulator sickness questionnaire (SSQ)at 1st session (an average of 3 days) and at study completion (an average of 1 month)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026